Landscapes / Companies
Kardigan, Inc. not checked
FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
2 in Phase 3
1 in Phase 2
Drugs
3
in active trials
Trials
4 active
5 since 2021
Drugs3
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
— |
Bristol Myers Squibb |
Phase 3 | Sep 2027Phase 2/3 trial completes | ||
| Next date | Sep 2027 · Phase 2/3 trial completes | ||||
| Also tested for | Symptomatic Genetic Dilated Cardiomyopathy, Symptomatic Genetic Dilated Cardiomyopathy (DCM) | ||||
| Open drug page | |||||
Guanylate cyclase activators and stimulator |
Phase 2/3 | 31 Aug 2028Phase 2/3 trial completes | |||
| How it works | Boosts a chemical signal (cGMP) that relaxes blood vessels and eases strain on the heart | ||||
| Next date | 31 Aug 2028 · Phase 2/3 trial completes | ||||
| Also tested for | Moderate Aortic Valve Stenosis | ||||
| Open drug page | |||||
— |
Ionis Pharmaceuticals |
Phase 2 | Dec 2026Phase 2 trial completes | ||
| Next date | Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Hypertension, Acute Severe Hypertension and 2 more | ||||
| Open drug page | |||||
About
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 Industry-sponsored drug trials since 2021